AveXis could be lifted by rival Spark Therapeutics' pricing scheme for gene therapy: RBC - (MarketWatch via NewsPoints Desk)

  • RBC Capital Markets analyst Brian Abrahams suggested that AveXis could indirectly benefit from payment arrangements made by Spark Therapeutics for the gene therapy Luxturna, MarketWatch reported Wednesday.

  • AveXis reported positive early-stage study results for its investigational gene therapy AVXS-101 in November last year.

  • Abrahams noted that the payment arrangement "helps set the stage for [AVXS-101] and other gene therapies," adding "we note this strategy is in distinct contrast to what had taken place with other one-time treatments as in [hepatitis C], and believe that this more proactive approach is more likely to ensure the buy-in of key constituents."

  • Abrahams suggested that the FDA could grant accelerated approval of AveXis' drug.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.